SCM
ETON icon

Soleus Capital Management’s Eton Pharmaceutcials ETON Stock Holding History

Soleus Capital Management’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-166,381
Closed -$4.11M – 103
2026
Q1 		$4.11M Buy
+166,381
New +$2.91M 0.17% 67
2025
Q4 		– Sell
-200,000
Closed -$4.35M – 102
2025
Q3 		$4.35M Sell
200,000
-85,000
-30% -$1.41M 0.22% 61
2025
Q2 		$4.06M Buy
+285,000
New +$4.51M 0.27% 57

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return

Soleus Capital Management's ETON Position: Q2 2026 in Review

Soleus Capital Management sold out of Eton Pharmaceutcials (ETON) in Q2 2026, closing a stake of 166,381 shares — an estimated $4.11M sold.

Soleus Capital Management first reported a position in ETON in Q2 2025 and held it in 3 quarters. The position peaked at $4.35M in Q3 2025. 164 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • Soleus Capital Management reported no remaining Eton Pharmaceutcials position as of Q2 2026 after selling out during the quarter.
  • Soleus Capital Management sold 166,381 Eton Pharmaceutcials shares in Q2 2026, an estimated $4.11M.
  • Soleus Capital Management first reported a position in Eton Pharmaceutcials in Q2 2025 and held it in 3 quarters.
  • Soleus Capital Management's Eton Pharmaceutcials position peaked at $4.35M in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.